Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 3/20 | 0.60 |
| ▸ | AURKA | O14965 | 1/20 | 0.57 |
| ▸ | TTK | P33981 | 1/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.57 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.57 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.50 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.50 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.50 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876885 | 0.87 | AXL (0.59) | AXLPIK3C3ALDH1A1GAANR4A2 | |
| SCHEMBL5781938 | 0.86 | NR4A2 (0.54) | ALDH1A1KDM4ENR4A2GABRA1GABRG2 | |
| SCHEMBL12427703 | 0.84 | SLC6A4 (0.49) | AXLPIK3C3PIK3CA | |
| SCHEMBL12427702 | 0.83 | CFTR (0.48) | AXLPIK3C3IKBKETBK1ALDH1A1 | |
| SCHEMBL11379519 | 0.82 | AXL (0.60) | AXLAURKATTKAURKBINCENP | |
| SCHEMBL11386246 | 0.82 | AXL (0.60) | AXLAURKATTKAURKBINCENP | |
| SCHEMBL3711387 | 0.80 | AAK1 (0.45) | AXLPIK3C3ALDH1A1KDM4ENR4A2 | |
| SCHEMBL5687509 | 0.80 | AXL (0.52) | AXLPIK3C3ALDH1A1KDM4EGAA | |
| SCHEMBL12427707 | 0.78 | SLC6A3 (0.57) | AXLPIK3C3ALDH1A1PIK3CDPIK3CA | |
| SCHEMBL29604147 | 0.77 | CHRNA7 (0.47) | PIK3C3PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254904-B1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | EISAI CO LTD (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-6784192-B2 | NA+ CHANNEL INHIBITORY ACTION IS USEFUL FOR THERAPY AND PREVENTION FOR EXAMPLE, ARRHYTHMIA, VARIOUS NEURALGIAS AND ANALGESIC | EISAI CO., LTD. (JP) | 2004-08-31 | — | — | US | disclosed |
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1254904-A1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
| US-4463008-A | 2-Alkoxy-5-(pyridinyl)pyridines and cardiotonic use thereof | STERLING DRUG INC. (US) | 1984-07-31 | — | — | US | disclosed |
| EP-0109027-A1 | Pyridine derivatives, process for their preparation and composition containing them | STERLING DRUG INC. (US) | 1984-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | TRPV1, CACNA1D, KCND2 | AXL 4859/4885AURKA 2019/4885TTK 3853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.